EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy

Jeremie Calais, Michael J Morris, Ayse Tuba Kendi, Arash Rezazadeh Kalebasty, Ronald Tutrone, Michael J Anderson, Oliver Sartor

Journal of Nuclear Medicine · 2024-11 · 65 (11) · 1666-1671

DOI: 10.2967/jnumed.124.268363 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.10.2024. Verfasst von Jeremie Calais und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Patient Care, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy approvals, such as radiopharmaceuticals. The prostate-specific membrane antigen (PSMA)-targeted agent 177Lu vipivotide tetraxetan ([177Lu]Lu-PSMA-617), approved after the phase III VISION study, presents physicians with additional aspects of patient management, including specific adverse event (AE) monitoring and management, as well as radiation safety. Drawing on our experience as VISION study investigators, here we provide guidance on best practices for delivering PSMA-targeted radiopharmaceutical therapy (RPT) to patients with mCRPC. After a comprehensive review of published evidence and guidelines on RPT management in prostate cancer, we identified educational gaps in managing the radiation safety and AEs associated with [177Lu]Lu-PSMA-617. Our results showed that providing sufficient education on AEs (e.g., fatigue and dry mouth) and radiation safety principles is key to effective delivery and management of patient expectations. Patient counseling by health care professionals, across disciplines, is a cornerstone of optimal patient management during PSMA-targeted RPT. Multidisciplinary collaboration is crucial, and physicians must adhere to radiation safety protocols and counsel patients on radiation safety considerations. Treatment with [177Lu]Lu-PSMA-617 is generally well tolerated; however, additional interventions may be required, such as dosing modification, medications, or transfusions. Urinary incontinence can be challenging in the context of radiation safety. Multidisciplinary collaboration between medical oncologists and nuclear medicine teams ensures that patients are monitored and managed safely and efficiently. In clinical practice, the benefit-to-risk ratio should always be evaluated on a case-by-case basis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, SurfaceGlutamate Carboxypeptidase IIPatient CareProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsHumansMaleMolecular Targeted Therapy

Stichwörter der Autor:innen

adverse eventsmetastatic castration-resistant prostate cancermultidisciplinary managementprostate-specific membrane antigenradiopharmaceutical therapy

Substanzen

Antigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIRadiopharmaceuticals

Autor:innen und Institutionen

  • Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
  • Department of Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology, Mayo Clinic, Rochester, Minnesota.
  • School of Medicine, University of California, Irvine, California.
  • Chesapeake Urology Research Associates, Towson, Maryland.
  • Department of Radiation Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada; and.

Förderung

  • NCI NIH HHS

Zitieren

APA

Calais, J., Morris, M. J., Kendi, A. T., Kalebasty, A. R., Tutrone, R., Anderson, M. J., & Sartor, O. (2024). Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 65(11), 1666-1671. https://doi.org/10.2967/jnumed.124.268363

Vancouver

Calais J, Morris MJ, Kendi AT, Kalebasty AR, Tutrone R, Anderson MJ, et al. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2024;65(11):1666-1671. doi:10.2967/jnumed.124.268363

BibTeX
@article{Calais2024,
  author = {Calais, Jeremie and Morris, Michael J and Kendi, Ayse Tuba and Kalebasty, Arash Rezazadeh and Tutrone, Ronald and Anderson, Michael J and Sartor, Oliver},
  title = {Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {11},
  pages = {1666--1671},
  doi = {10.2967/jnumed.124.268363}
}
Kostenlos starten →